Stay updated on Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial page.

Latest updates to the Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial page
- Check5 days agoChange DetectedFooter now displays Revision: v3.4.3 and the previous Revision: v3.4.2 label was removed.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2 and removed the government funding lapse notice, which are minor site maintenance updates that do not affect the study details or core content on this page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and updated the revision to v3.4.1 (from v3.4.0).SummaryDifference0.4%

- Check48 days agoChange DetectedAdded a 'Show glossary' option and updated metadata labels, including a new 'Last Update Submitted that Met QC Criteria' field and a capitalization change to 'No FEAR Act data'. Replaced the version label with v3.4.0.SummaryDifference0.2%

- Check62 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4. No substantive changes to the study details.SummaryDifference0.1%

- Check83 days agoChange DetectedA dedicated Locations section has been added, listing Washington (Seattle, Washington) as a study site.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial page.